Hand Actual Hygiene Compliance Data: Upper Saco Meds 100% Upper Kennebec Meds – –100% Upper Saco Milieu 7AM-7PM 100% Upper Kennebec Milieu 7AM-7PM 100% – – Upper Saco Milieu 7PM-7AM 100% Upper Kennebec Milieu 7PM-7AM 100% – – Lower Kennebec Meds 90% Lower Saco Meds 100% – – Lower Kennebec Milieu 7AM-7PM 100% Lower Saco Milieu 7AM-7PM – –100% Lower Kennebec Milieu 7PM-7AM 100% Lower Saco Milieu 7PM-7AM 100% – – Plan: Continue to monitor and measure. III. Measure Name: Assisting Patients with Hygiene Measure Description: Staff offer hand gel to patients prior to breakfast, lunch, and dinner, ten (10) days per month. Measure Type: Quality Assurance Results Unit Baseline 1Q2016 2Q2016 3Q2016 4Q2016 YTD Employee >90% >90% >90% >90% >90% Target Hand 88% Hygiene FY 2016 98% 98% Compliance Actual Data: The mean compliance rate for July 2016 is 97%. The mean compliance rate for August 2016 is 98%. The mean compliance rate for September 2016 is 100%. Plan: Continue to monitor and measure. Medication Errors and Adverse Reactions
Hand Hygiene Compliance Actual Data: Upper Saco Meds – 100% Upper Kennebec Meds –100% Upper Saco Milieu 7AM-7PM – 100% Upper Kennebec Milieu 7AM-7PM – 100% Upper Saco Milieu 7PM-7AM – 100% Upper Kennebec Milieu 7PM-7AM – 100% Lower Kennebec Meds – 90% Lower Saco Meds – 100% Lower Kennebec Milieu 7AM-7PM – 100% Lower Saco Milieu 7AM-7PM –100% Lower Kennebec Milieu 7PM-7AM – 100% Lower Saco Milieu 7PM-7AM – 100% Plan: Continue to monitor and measure. III. Measure Name: Assisting Patients with Hygiene Measure Description: Staff offer hand gel to patients prior to breakfast, lunch, and dinner, ten (10) days per month. Measure Type: Quality Assurance Results Unit Baseline 1Q2016 2Q2016 3Q2016 4Q2016 YTD Target Employee Hand Hygiene Compliance 88% FY 2016 >90% >90% >90% >90% >90% Actual 98% 98% Data: The mean compliance rate for July 2016 is 97%. The mean compliance rate for August 2016 is 98%. The mean compliance rate for September 2016 is 100%. Plan: Continue to monitor and measure. Medication Errors and Adverse Reactions
2017Q1.docx